Inspira Technologies Oxy B.H.N. Ltd. IINN 深 沪
已收盘 02-06 16:00:00 美东时间
0.7132
+0.063
+9.72%
华盛通- 最 高0.7589
- 今 开0.67
- 成交量 9.83万股
- 最 低 0.6601
- 昨 收 0.65
- 总市值 2563.90万
- 52周最高 1.65
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 0.4026
- 委 比 -17.43%
- 总股本 3594.92万
- 历史最高 9.59
- 量 比 0.47
- 振 幅 15.20%
- 历史最低 0.4026
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inspira Technologies OXY Commences ~$.75M Offering Of 6.785M Common Shares At $0.70/Share
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that
02-05 21:12
Inspira Technologies' INSPIRA ART100 System Clears Its Full Clinical Evaluation, Progresses To Budgeted Procurement Execution Process
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S.
01-29 21:40
Inspira Technologies' $22.5M And $27M Government Purchase Orders Advance To Final Budget Approval, Expected To Drive 2026 Revenue
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant
01-21 21:53
Inspira Technologies Enters Non-Binding Term Sheet For The Acquisition Of An Advanced Liquid Biopsy Business, Together With A Concurrent $15M Strategic Equity Investment Into The Company; Expects To Finalize Withing Next 4-Weeks
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has entered into a non-binding term sheet (the
01-05 22:34
Inspira Technologies Reaffirms $49.5M Binding Purchase Orders; Payments To Commence FY2026 Aligned With Regulatory And Deployment Milestones
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders
2025-12-23 21:32
Inspira Technologies Announces Strategic Expansion Of Core Blood Laboratory Capabilities For Accelerated Future Growth
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of
2025-12-03 21:45
Inspira Technologies Completes Regulatory Requirement Of Its INSPIRA ART100 System To UAE Ministry Of Health And Prevention
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has completed
2025-11-06 22:14
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem
Inspira Technologies has entered into a strategic collaboration with Bites Learning to integrate Bites' AI-powered learning platform into Inspira's medical devices, enhancing training and operational efficiency for global customers. This partnership aims to simplify onboarding, reduce support burdens, and create a competitive edge for Inspira.
2025-10-22 12:30
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies has appointed Mike Hershkovitz as Vice President of Global Sales and Sivan Matza to its Board of Directors. Hershkovitz brings over 20 years of experience in healthcare sales, while Matza, an expert in global finance, joins as an independent director. These appointments aim to enhance the Company's commercial expansion and governance.
2025-10-21 13:05
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira Technologies reported strong progress in the first half of 2025, securing $49.5 million in binding purchase orders and achieving 97.35% accuracy for its HYLA blood sensor. The company expanded clinical use of its ART100 system in leading hospitals and received U.S. patent protection for its core technology. Despite increased operating expenses, Inspira anticipates revenue recognition from these orders starting in 2026 and targeting an ann...
2025-10-01 12:00
